Antibiotics may impair hematopoietic recovery after cytotoxic myeloablation

Blood

Volumn 113, Issue 7, 2009, Pages 1608-1609

  Tjwa, Marc ^b   Moons, Lieve ^b   Verfaillie, Catherine ^b   Carmeliet, Peter ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; DOXYCYCLINE; FLUOROURACIL; GELATINASE A; GELATINASE B; MACROPHAGE ELASTASE;

BONE MARROW; BONE MARROW TOXICITY; CYTOTOXICITY; DRUG INHIBITION; GENETICS; HEMATOPOIESIS; HEMATOPOIETIC CELL; IMMUNOHISTOCHEMISTRY; LETTER; LEUKOCYTE; LEUKOCYTOSIS; LEUKOPENIA; NONHUMAN; PRIORITY JOURNAL; STEADY STATE;

EID: 61849115674     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-10-185694     Document Type: Letter

References (5)

1. Smith GN Jr, Mickler EA, Hasty KA, Brandt KD. Specificity of inhibition of matrix metalloproteinase activity by doxycycline: relationship to structure of the enzyme. Arthritis Rheum. 1999;42:1140-1146.
2. Pyo R, Lee JK, Shipley JM, et al. Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest. 2000;105:1641-1649.
3. Jonat C, Chung FZ, Baragi VM. Transcriptional downregulation of stromelysin by tetracycline. J Cell Biochem. 1996;60:341-347.
4. Heissig B, Hattori K, Dias S, et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell. 2002;109:625-637.
5. Tjwa M, Carmeliet P, Moons L. Novel transgenic rabbit model sheds light on the puzzling role of matrix metalloproteinase-12 in atherosclerosis. Circulation. 2006;113:1929-1932.